Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28278368 | 0.94 | MAPT (0.45) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL4225099 | 0.78 | MAPT (0.40) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL21670228 | 0.77 | MAPT (0.39) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL2839539 | 0.76 | MAPT (0.38) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL3624905 | 0.75 | GRM2 (0.32) | — | |
| SCHEMBL28177553 | 0.75 | KMT2A (0.38) | MAPTNPSR1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL4050823 | 0.73 | MAPT (0.46) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL27991277 | 0.69 | LMNA (0.32) | LMNA | |
| SCHEMBL1709532 | 0.65 | CYP3A4 (0.45) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL9583315 | 0.65 | NPSR1 (0.37) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893579-B1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-05-01 | — | — | EP | disclosed |
| US-7816380-B2 | 1-hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2009-03-05 | — | — | US | disclosed |
| EP-1893579-A1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006132837-A1 | l-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, HRH4 | MAPT 4223/4885NPSR1 334/4885ALDH1A1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.